Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 7297 - 7304 of 12008 results
Is Trump's Travel Ban on Fast Track to Supreme Court?
February 10, 2017| News
Update: Appellate Court Rejects Administration’s Effort to Reinstate Travel Ban
February 10, 2017| Alert| Viewpoint
GOP Senior Statesmen Call for Carbon Tax
February 9, 2017| Blog| Viewpoint
CPSC Begins Transition: Ann Marie Buerkle is Now the Acting Chairman of the Agency
February 9, 2017| Blog| Viewpoint
St. Jude Cybersecurity Vulnerability Extended to Provider-Owned Devices
February 9, 2017| Blog| Viewpoint
Ruling Vacating Target Consumer Class Settlement Highlights The Problem Of Standing In Data Breach Cases
February 9, 2017| Blog| Viewpoint
New Rules in the Northern District of California Aim to Encourage Patent Case Settlements
February 8, 2017| Blog| Viewpoint
Securities and Exchange Commission Considers Changes to CEO Pay Ratio Rule
February 8, 2017| Blog| Viewpoint
News & Press Releases
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Mintz represented S2G Investments, a multi-stage investment firm focused on venture and growth-stage businesses across food & agriculture, oceans and energy, in its $40 million Series B financing of Sojo Industries, an industrial automation company that utilizes robotics, mobility, and software to deliver packaging and assembly solutions to the food and beverage industry.
Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|